PERSPECTIVE THERAPEUTICS, INC. Cost of Revenue
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Cost of Revenue of $1.45 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2023-11-14
- PERSPECTIVE THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2023-09-30 was $1.45M, a 11.05% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2023-06-30 was $1.84M, a 16.53% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2023-03-31 was $1.58M, a 7.28% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2022-12-31 was $1.43M, a 10.28% decline year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. cost of goods and services sold for fiscal 2022 was $6.18M, a 25.28% increase from fiscal 2021.
- PERSPECTIVE THERAPEUTICS, INC. cost of goods and services sold for fiscal 2021 was $4.93M, a 8.25% increase from fiscal 2020.
- PERSPECTIVE THERAPEUTICS, INC. cost of goods and services sold for fiscal 2020 was $4.56M, a 6.77% increase from fiscal 2019.
- PERSPECTIVE THERAPEUTICS, INC. cost of goods and services sold for fiscal 2019 was $4.27M, a 4.56% increase from fiscal 2018.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.45M 10-Q · filed 2023-11-14 | $3.29M derived: sum of 2 quarters · filed 2023-11-14 | $4.86M 10-Q · filed 2023-11-14 | $6.29M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $1.84M 10-Q · filed 2023-08-11 | $3.42M 10-Q · filed 2023-08-11 | $4.85M derived: sum of 3 quarters · filed 2023-08-11 | $6.15M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $1.58M 10-Q · filed 2023-05-15 | $3.01M derived: sum of 2 quarters · filed 2023-05-15 | $4.31M derived: sum of 3 quarters · filed 2023-11-14 | $5.89M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $1.43M derived: 10-KT 6 month − 10-Q 3 month · filed 2023-05-01 | $2.73M 10-KT · filed 2023-05-01 | $4.31M derived: sum of 3 quarters · filed 2023-11-14 | $5.78M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-09-30 | $1.30M 10-Q · filed 2023-11-14 | $2.88M derived: sum of 2 quarters · filed 2023-11-14 | $4.35M 10-Q · filed 2023-11-14 | $5.95M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.58M 10-Q · filed 2023-08-11 | $3.05M 10-Q · filed 2023-08-11 | $4.64M derived: sum of 3 quarters · filed 2023-08-11 | $6.18M 10-KT · filed 2023-05-01 |
| 2022-03-31 | $1.47M 10-Q · filed 2023-05-15 | $3.06M derived: sum of 2 quarters · filed 2023-05-15 | $4.60M 10-Q · filed 2022-05-13 | $5.96M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.60M 10-Q · filed 2022-02-09 | $3.13M 10-KT · filed 2023-05-01 | $4.50M derived: sum of 3 quarters · filed 2023-05-01 | $5.73M derived: sum of 4 quarters · filed 2023-05-01 |
| 2021-09-30 | $1.53M 10-Q · filed 2022-11-14 | $2.90M derived: sum of 2 quarters · filed 2023-05-01 | $4.14M derived: sum of 3 quarters · filed 2023-05-01 | $5.33M derived: sum of 4 quarters · filed 2023-05-01 |
| 2021-06-30 | $1.36M derived: 10-KT 12 month − 10-Q 9 month · filed 2023-05-01 | $2.60M derived: sum of 2 quarters · filed 2023-05-01 | $3.79M derived: sum of 3 quarters · filed 2023-05-01 | $4.93M 10-KT · filed 2023-05-01 |
| 2021-03-31 | $1.24M 10-Q · filed 2022-05-13 | $2.43M derived: sum of 2 quarters · filed 2022-05-13 | $3.57M 10-Q · filed 2022-05-13 | $4.78M derived: sum of 4 quarters · filed 2023-05-01 |
| 2020-12-31 | $1.19M 10-Q · filed 2022-02-09 | $2.33M 10-Q · filed 2022-02-09 | $3.54M derived: sum of 3 quarters · filed 2023-05-01 | $4.71M derived: sum of 4 quarters · filed 2023-05-01 |
| 2020-09-30 | $1.14M 10-Q · filed 2021-11-10 | $2.35M derived: sum of 2 quarters · filed 2023-05-01 | $3.52M derived: sum of 3 quarters · filed 2023-05-01 | $4.62M derived: sum of 4 quarters · filed 2023-05-01 |
| 2020-06-30 | $1.21M derived: 10-KT 12 month − 10-Q 9 month · filed 2023-05-01 | $2.38M derived: sum of 2 quarters · filed 2023-05-01 | $3.48M derived: sum of 3 quarters · filed 2023-05-01 | $4.56M 10-KT · filed 2023-05-01 |
| 2020-03-31 | $1.17M 10-Q · filed 2021-05-14 | $2.27M derived: sum of 2 quarters · filed 2021-05-14 | $3.35M 10-Q · filed 2021-05-14 | $4.39M derived: sum of 4 quarters · filed 2021-09-27 |
| 2019-12-31 | $1.09M 10-Q · filed 2021-02-09 | $2.17M 10-Q · filed 2021-02-09 | $3.22M derived: sum of 3 quarters · filed 2021-09-27 | $4.26M derived: sum of 4 quarters · filed 2021-09-27 |
| 2019-09-30 | $1.08M 10-Q · filed 2020-11-13 | $2.12M derived: sum of 2 quarters · filed 2021-09-27 | $3.17M derived: sum of 3 quarters · filed 2021-09-27 | $4.31M derived: sum of 4 quarters · filed 2021-09-27 |
| 2019-06-30 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-27 | $2.09M derived: sum of 2 quarters · filed 2021-09-27 | $3.23M derived: sum of 3 quarters · filed 2021-09-27 | $4.27M 10-K · filed 2021-09-27 |
| 2019-03-31 | $1.04M 10-Q · filed 2020-05-13 | $2.18M derived: sum of 2 quarters · filed 2020-05-13 | $3.22M 10-Q · filed 2020-05-13 | $4.39M derived: sum of 4 quarters · filed 2020-09-25 |
| 2018-12-31 | $1.14M 10-Q · filed 2020-02-12 | $2.18M 10-Q · filed 2020-02-12 | $3.34M derived: sum of 3 quarters · filed 2020-09-25 | $4.31M derived: sum of 4 quarters · filed 2020-09-25 |
| 2018-09-30 | $1.04M 10-Q · filed 2019-11-13 | $2.20M derived: sum of 2 quarters · filed 2020-09-25 | $3.17M derived: sum of 3 quarters · filed 2020-09-25 | $4.17M derived: sum of 4 quarters · filed 2020-09-25 |
| 2018-06-30 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-25 | $2.13M derived: sum of 2 quarters · filed 2020-09-25 | $3.13M derived: sum of 3 quarters · filed 2020-09-25 | $4.08M 10-K · filed 2020-09-25 |
| 2018-03-31 | $964.00K 10-Q · filed 2019-05-10 | $1.97M derived: sum of 2 quarters · filed 2019-05-10 | $2.92M 10-Q · filed 2019-05-10 | $3.79M derived: sum of 4 quarters · filed 2019-09-27 |
| 2017-12-31 | $1.00M 10-Q · filed 2019-02-13 | $1.95M 10-Q · filed 2019-02-13 | $2.82M derived: sum of 3 quarters · filed 2019-09-27 | $3.81M derived: sum of 4 quarters · filed 2019-09-27 |
| 2017-09-30 | $946.00K 10-Q · filed 2018-11-09 | $1.82M derived: sum of 2 quarters · filed 2019-09-27 | $2.81M derived: sum of 3 quarters · filed 2019-09-27 | |
| 2017-06-30 | $872.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-27 | $1.86M derived: sum of 2 quarters · filed 2019-09-27 | $3.92M 10-K · filed 2019-09-27 | |
| 2017-03-31 | $989.00K 10-Q · filed 2018-05-04 | $3.05M 10-Q · filed 2018-05-04 | ||
| 2016-06-30 | $4.64M 10-K · filed 2018-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |